Diets · Metabolic & Cardiometabolic
LDL cholesterol increases cardiovascular risk
In plain terms: Is high LDL on a carnivore diet still a heart concern?
Strong support Diets 💰 Industry COI noted🔬 Includes disconfirming⚠️ Includes retracted (not counted)
RefutedContestedStrong support
consensus score 0.92
Yes — LDL/ApoB is causal for atherosclerosis by genetics and trials; there is no evidence carnivore-induced high LDL is exempt, so Baker's dismissal is not supported.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
5 support 2 contradict 0 tested null 0 mixed · 7 sources, 6 independent groups · 1 retracted, not counted
What the evidence shows
LDL and ApoB are causal for atherosclerosis on both genetics and trials: a meta-analysis of 21 randomised trials in 184,012 patients shows lowering LDL lowers events, including in primary prevention and in populations already starting below 70 mg/dL. Nothing exempts diet-induced high LDL, and the contrary evidence here is a case report and a cross-sectional comparison.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sánchez-Quesada JL, Pérez A 2026 · Front Endocrinol | observational | supports | low | An opinion article, not a study: it reports no new data of its own and argues from other groups' work that LDL-C is a causal, cumulative cause of atherosclerosis, so cardiovascular risk reflects a lifetime of exposure rather than one measurement. It cites Mendelian randomisation in which lifelong genetically lower LDL-C tracks roughly 50-55% lower coronary risk per 1 mmol/L, a larger effect than drug lowering begun in adulthood. Low-carbohydrate and carnivore diets are never discussed, and the authors describe the piece as complementing, not replacing, existing guidelines. |
| Budoff M, Manubolu VS, Kinninger A, Norwitz NG, Feldman D, Wood TR, Fialkow J, Cury R, Feldman T, Nasir K 2024 · JACC Adv | observational | contradicts | low | Cross-sectional matched comparison: 80 adults on a carbohydrate-restricted diet a mean 4.7 years (LDL-C 272 ± 91 mg/dL) vs 80 Miami Heart controls (123 ± 38), matched on age, sex, race and risk factors. 'There was no significant difference in coronary plaque burden': calcium score 0 (IQR 0-56) vs 1 (0-49), P = 0.520; plaque score 0 (0-2) vs 1 (0-4), P = 0.245; LDL-C did not correlate with plaque (r = 0.12, P = 0.29). A weak null: 80 per group, median plaque 0 in both arms, no repeat imaging, one LDL-C measurement, and 26 of 80 controls (33%) took lipid-lowering drugs against none on the diet. |
| Norwitz NG, Soto-Mota A, Feldman D, Parpos S, Budoff M 2022 · Front Endocrinol | observational | contradicts | low | Single case report (n=1): a 26-year-old man on a ketogenic diet adopted for ulcerative colitis, whose LDL-C rose from 95 mg/dl pre-diet to a peak of 545 mg/dl (HDL-C 94, TG 58), with elevated Lp(a) 109-168 mg/dl. After exposure to 'LDL-C ~400–550 for ~2.5 years' and 'a prior CAC of 0', a single coronary CT angiogram found 'No plaque or stenosis was observed in any vessels CAD-RADS = 0'. The authors caution that 'two and half years is insufficient for any measurable atherosclerotic plaque to precipitate' and that 'his results cannot be assumed to be generalizable'. |
| Soto-Mota A, Norwitz NG, ... Budoff M 2025 · JACC Adv (RETRACTED 2026) | observational | contradicts | low | RETRACTED in 2026: “concerns were raised regarding the methodology in this article, which effect the reliability of the data”; “the identified errors are too great to be corrected with a corrigendum.” Single-arm 1-year CT-angiography study of 100 people on a ketogenic diet with LDL-C ≥190 mg/dL (mean 254 mg/dL, ApoB 185 mg/dL). It reported “neither total exposure nor changes in baseline levels of ApoB and LDL-C were associated with changes in plaque,” while plaque still rose a median 18.9 mm3. No comparator group; funded by the Citizen Science Foundation. ⚠️ RETRACTED — not counted |
| Kalra, Ray, Bajaj, Kushner, Wilcox, Dicklin, Kirkpatrick, Maki 2026 · J Clin Lipidol 2026;20(4):738-749 | meta-analysis | supports | high | Meta-analysis of 14 primary-prevention LDL-lowering outcomes trials: 'In CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated with a 30% RRR in 4-point MACE' (RR 0.70; 95% CI 0.67-0.74). This supports LDL-C as a modifiable cardiovascular risk factor in people without established disease; the paper's own wording is 'was associated with', and pooled drug trials are not a causal-inference design in the Mendelian-randomization sense, so the earlier 'confirming LDL-C as a causal ... risk factor' phrasing is dropped. The claim's discriminating modifier - 'even on a low-carb or carnivore diet' - is UNTESTED here: diet is not an exposure, stratifier or subgroup in this corpus of drug trials (same limitation recorded for s30073316 and s33186535). Abstract-only read; heavy author industry COI. |
| Sabatine, Wiviott, Im, Murphy, Giugliano 2018 · JAMA Cardiol. 2018 Sep 1;3(9):823-828 | meta-analysis | supports | high | Meta-analysis of trials whose populations already START at median LDL-C 1.8 mmol/L (70 mg/dL) or less: further lowering still cut major vascular events - statin subgroup RR 0.78 (95% CI 0.65-0.94, 1,922 events), 3 nonstatin add-on trials RR 0.79 (0.70-0.88; 50,627 patients, 9,570 events), combined RR 0.79 (0.71-0.87, P < .001) per 1 mmol/L, holding down to a median achieved 0.5 mmol/L (21 mg/dL) with no offsetting harms detected. Supports LDL causality with no evident threshold. SCOPE CAVEAT: no low-carb or carnivore population is studied here - diet is not an exposure, stratifier or subgroup anywhere in the paper, so the claim's dietary qualifier is untested by this source (as it is by its 11 siblings; routed as a claim-level question, not cut here). |
| Cooper ID, Sanchez-Pizarro C, Norwitz NG, Feldman D, Kyriakidou Y, Edwards K, Petagine L, Elliot BT, Soto-Mota A 2023 · Front Endocrinol | observational | mixed | low | Non-randomized, open-label crossover in 10 lean healthy premenopausal women cycling through 21 days of ketosis, 21 days of carbohydrate reintroduction and 21 days of ketosis. Mean LDL-C was 148.0, 102.5 and 124.1 mg/dL across the three phases (p = 0.12), and lower BMI predicted larger LDL-C change (β = −25.1, p = 0.001, 42% of variance explained); free T3 also predicted it, saturated fat did not. The paper does not report cardiovascular events, coronary imaging or any other cardiovascular outcome. |
| Pirillo A, Casula M, Olmastroni E, Scotti S, Corsini A, Catapano AL 2026 · Pharmacol Rev. 2026 Jul;78(4):100140 | observational | supports | low | A narrative pharmacology review, not a study: it reports no new data and argues from genetics, Mendelian randomization and trials that elevated LDL-C is 'recognized as a causal factor and the primary target for the prevention of atherosclerotic cardiovascular disease', that cumulative lifetime LDL-C exposure drives risk, and that early lowering reduces events. It gives no pooled estimate of its own, and low-carbohydrate or carnivore diets are never discussed. Three of six authors, the senior author included, disclose honoraria or grants from lipid-drug manufacturers. |
| Wang N, Woodward M, Huffman MD, Rodgers A 2022 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Meta-analysis of 21 randomised trials of statins, ezetimibe and PCSK9 inhibitors in 184,012 patients, average follow-up 4.4 years, found that lowering LDL cholesterol reduced major vascular events and that the benefit grew with time on treatment: a 12% relative risk reduction per 1 mmol/L (95% CI 8-16%) in year 1, rising to 20% at year 3, 23% at year 5 and 29% (14-42%) at year 7. The trials enrolled general adult populations; nobody in them was tested on a low-carbohydrate or carnivore diet. |
| Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL 2022 · Eur Heart J | observational | supports | moderate | The 2022 European Atherosclerosis Society consensus statement on lipoprotein(a). A 22-author panel concludes that 'Observational and genetic evidence convincingly demonstrates that high Lp(a) concentration is causal for ASCVD, AVS and cardiovascular and all-cause mortality in men and women and across ethnic groups', and that 'elevated Lp(a) is a risk factor even at very low LDL-C concentration'. LDL-C enters only as the background level against which Lp(a) risk is judged; the statement reports no analysis of LDL cholesterol itself as a cardiovascular exposure, and studies no diet. |
| Lincoff AM, Ray KK, Sasiela WJ, Haddad T, Nicholls SJ, Li N, Cho L, Mason D, Libby P, Goodman SG, Nissen SE 2024 · J Am Coll Cardiol | RCT | supports | moderate | CLEAR Outcomes randomised 13,970 statin-intolerant patients to bempedoic acid or placebo. A first major vascular event occurred in 703 (10.1%) on the drug versus 816 (11.7%) on placebo, a hazard ratio of 0.85 (95% CI 0.77-0.94). Scaled to a 1 mmol/L reduction in LDL cholesterol the hazard ratio was 0.75 (0.63-0.90), close to the 0.78 statins achieve for the same LDL drop, so lowering LDL without a statin bought the same benefit per unit. The analyses were run by the sponsor's statisticians. No participant was on a low-carb or carnivore diet. |
| Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MS 2020 · Lancet | meta-analysis | supports | high | Supports the general core; silent on the dietary context. In 21 492 patients aged >=75 across 29 RCTs, 'LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (RR 0·74 [95% CI 0·61-0·89]; p=0·0019)', consistent across cardiovascular death, MI, stroke and revascularisation. Scope limit to record: every participant is in a DRUG-treatment outcome trial — no low-carb or carnivore exposure is studied — so this evidences LDL as a modifiable CV risk factor generally, not the claim's 'even on a low-carb or carnivore diet' modifier. (Abstract-grade.) |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.